Other Clinical Trial - Study of Varlitinib Plus Capecitabine in Patients

Clinical Trial Description

Also to explore the role of biomarkers as predictors of response and clinical benefit with varlitinib ;

Study Design

Related Conditions & MeSH terms

Advanced or Metastatic Biliary Tract Cancer
Biliary Tract Neoplasms

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04837508` - A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer	Phase 2
Completed	`NCT03082053` - A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours	Phase 1
Recruiting	`NCT04838964` - A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer	Phase 2

See also

Status

Clinical Trial

Phase

Recruiting

NCT04837508 - A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Phase 2

Completed

NCT03082053 - A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours

Phase 1

Recruiting

NCT04838964 - A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03129074
Study type	Interventional
Source	Aslan Pharmaceuticals
Contact
Status	Withdrawn
Phase	Phase 2
Start date	May 2018
Completion date	September 2020

Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms